Search
01/01/2022
Advanced lipoprotein profile in individuals with normal and impaired glucose metabolism
Puig-Jove, C, Castelblanco, E, Falguera, M, Hernandez, M, Soldevila, B, Julian, MT, Teis, A, Julve, J, Barranco-Altirriba, M, Franch-Nadal, J, Puig-Domingo, M, Ortega, E, Amigo, N, Alonso, N, Mauricio, D. Advanced lipoprotein profile in individuals with normal and impaired glucose metabolism. REVISTA ESPANOLA DE CARDIOLOGIA. 2022; 75(1)DOI:10.1016/j.recesp.2021.02.013. PMID:33785266. IF:5.900(Q1/3D).
01/01/2022
Perfil lipoproteico por espectroscopia nuclear magnética en pacientes con insuficiencia cardiaca crónica comparado con controles emparejados
Teis A., Castelblanco E., Cediel G., Amigó N., Julve J., Ribalta J., Guardiola M., Franch J., Bermúdez-López M., Codina P., Lupón J., Mauricio D., Alonso N., Bayés-Genís A.. Perfil lipoproteico por espectroscopia nuclear magnética en pacientes con insuficiencia cardiaca crónica comparado con controles emparejados. REVISTA ESPANOLA DE CARDIOLOGIA. 2022; 75(11)DOI:10.1016/j.recesp.2021.09.007. PMID:. IF:(Q/D).
01/01/2022
Acute-to-Chronic Glycemic Ratio as a Predictor of COVID-19 Severity and Mortality
Ramon, J, Llaurado, G, Guerri, R, Climent, E, Ballesta, S, Benaiges, D, Lopez-Montesinos, I, Navarro, H, Fernandez, N, Carrera, MJ, Mauricio, D, Flores-Le Roux, JA, Chillaron, JJ. Acute-to-Chronic Glycemic Ratio as a Predictor of COVID-19 Severity and Mortality. DIABETES CARE. 2022; 45(1)DOI:10.2337/dc21-1321. PMID:34782352. IF:16.200(Q1/1D).
01/01/2022
Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world
Franch-Nadal J., Granado-Casas M., Mata-Cases M., Ortega E., Vlacho B., Mauricio D.. Determinants of response to the glucagon-like peptide-1 receptor agonists in a type 2 diabetes population in the real-world. Primary Care Diabetes. 2022; 16(6)DOI:10.1016/j.pcd.2022.10.005. PMID:36336605. IF:2.900(Q2/5D).
01/01/2022
Obesity and related comorbidities in a large population-based cohort of subjects with type 1 diabetes in Catalonia
Genua I., Franch-Nadal J., Navas E., Mata-Cases M., Giménez-Pérez G., Vlacho B., Mauricio D., Goday A.. Obesity and related comorbidities in a large population-based cohort of subjects with type 1 diabetes in Catalonia. Frontiers in Endocrinology. 2022; 13DOI:10.3389/fendo.2022.1015614. PMID:36531459. IF:5.200(Q1/3D).
01/01/2022
Dysglycemia in young women attenuates the protective effect against fatty liver disease
Pérez-Montes de Oca A., Julián M.T., Pera G., Caballería L., Morillas R., Torán P., Expósito C., Franch-Nadal J., Mauricio D., Alonso N.. Dysglycemia in young women attenuates the protective effect against fatty liver disease. Frontiers in Endocrinology. 2022; 13DOI:10.3389/fendo.2022.971864. PMID:36479218. IF:5.200(Q1/3D).
01/01/2022
Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients: Results from the Spanish National Registry
Moreno-Fernandez J., Chico A., Martínez-Brocca M.A., Beato-Víbora P.I., Vidal M., Piedra M., Quirós C., Muñoz-Rodríguez J.R.. Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients: Results from the Spanish National Registry. Diabetes Technology & Therapeutics. 2022; 24(12)DOI:10.1089/dia.2022.0207. PMID:35947087. IF:5.400(Q1/3D).
01/01/2022
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study
Casas J.A.V., Sambo M., López C.L., Durán-Poveda M., García J.R.-V., Santos R.J., Llanos M., Navarro-González E., Aller J., Pubul V., Guadalix S., Crespo G., González C., Zafón C., Navarro M., Santamaría-Sandi J., Segura Á., Gajate P., Gómez-Balaguer M., Valdivia J., Puig-Domingo M., Galofré J.C., Castelo B., Villanueva M.J., Argüelles I., Orcajo-Rincón L.. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study. European Thyroid Journal. 2022; 11(5)DOI:10.1530/ETJ-21-0111. PMID:35900793. IF:4.700(Q2/3D).